Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

The problem of fibrosing interstitial lung diseases (ILDs) unites specialists from different areas: pulmonologists, radiologists, therapists, rheumatologists, occupational doctors and others. Actual achievements in studying fibrosing ILDs which are connected with development of immunology and molecu...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Научно-практическая ревматология
المؤلفون الرئيسيون:	L. P. Ananieva, S. N. Avdeev, I. Е. Tyurin, A. М. Lila, A. I. Zagrebneva, А. L. Maslyanskiy, S. A. Terpigorev, I. V. Stepanyan, E. L. Lashina, O. V. Vasilieva, O. S. Lukina, E S. Pershina, А. А. Klimenko, N. A. Shostak, E. L. Nasonov
التنسيق:	مقال
اللغة:	الروسية
منشور في:	IMA PRESS LLC 2021-01-01
الموضوعات:	interstitial lung diseases immune-inflammatory rheumatic diseases antifibrotic therapy nintedanib
الوصول للمادة أونلاين:	https://rsp.mediar-press.net/rsp/article/view/2960

مواد مشابهة

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
حسب: Yasuhiro Kondoh, وآخرون
منشور في: (2025-05-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
حسب: E. L. Nasonov, وآخرون
منشور في: (2022-12-01)

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology
حسب: E. L. Nasonov, وآخرون
منشور في: (2018-06-01)

The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry
حسب: Cathryn T. Lee, وآخرون
منشور في: (2024-06-01)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
حسب: Carlo Albera, وآخرون
منشور في: (2021-09-01)

Nintedanib in chronic fibrosing interstitial lung diseases. A case series
حسب: Raquel García Sevila, وآخرون
منشور في: (2024-04-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
حسب: Hikmet COBAN, وآخرون
منشور في: (2025-06-01)

A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
حسب: A. V. Teteneva, وآخرون
منشور في: (2021-10-01)

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
حسب: Hironao Hozumi, وآخرون
منشور في: (2024-07-01)

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention
حسب: Vito D’Agnano, وآخرون
منشور في: (2024-02-01)

Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?
حسب: Karol Bączek, وآخرون
منشور في: (2024-08-01)

The Role of Nintedanib in the Treatment of Progressive Pulmonary Fibrosis of Autoimmune-Related Interstitial Lung Disease
حسب: Aulia Rahman Ardan, وآخرون
منشور في: (2023-11-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
حسب: Nesrin Ocal, وآخرون

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
حسب: Jin-Young Huh, وآخرون
منشور في: (2023-12-01)

The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis
حسب: Francesco Rocco Bertuccio, وآخرون
منشور في: (2025-09-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
حسب: Sebastian Majewski, وآخرون
منشور في: (2025-06-01)

The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks
حسب: Hsin-Yi Wang, وآخرون
منشور في: (2024-04-01)

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
حسب: Fabio Perrotta, وآخرون
منشور في: (2024-06-01)

Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study
حسب: Francesca Lalla, وآخرون
منشور في: (2025-10-01)

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
حسب: Vinod K. Viswanathan, وآخرون
منشور في: (2024-09-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
حسب: Stefano Kette, وآخرون
منشور في: (2025-03-01)

Pulmonary fibrosis: New horizons and clinical solutions: A review II Expert Council “Idiopathic pulmonary fibrosis and progressive pulmonary fibroses. Real Practice” Symposium Review October 26, 2024, Sochi, Russia
حسب: Sergey N. Avdeev, وآخرون
منشور في: (2025-01-01)

Ways to improve the diagnosis and treatment of interstitial lung disease associated with systemic sclerosis in the Siberian Federal District (materials of the advisory board of rheumatologists and pulmonologists from December 08, 2019)
حسب: L. I. Alekseeva, وآخرون
منشور في: (2020-10-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
حسب: E. Bargagli, وآخرون
منشور في: (2019-05-01)

Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study
حسب: Yusuke Ushio, وآخرون
منشور في: (2024-06-01)

Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes
حسب: Svetlana Chikina, وآخرون
منشور في: (2023-02-01)

Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
حسب: Carla R. Copeland, وآخرون
منشور في: (2021-10-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
حسب: S. N. Avdeev, وآخرون
منشور في: (2018-10-01)

Nintedanib treatment for bleomycin-induced lung injury - First report
حسب: Dina Rnjak, وآخرون
منشور في: (2023-01-01)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
حسب: Paolo Cameli, وآخرون
منشور في: (2022-08-01)

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
حسب: Kodai Kawamura, وآخرون
منشور في: (2019-06-01)

The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019)
حسب: S. N. Avdeev, وآخرون
منشور في: (2020-03-01)

Treatment with low‐dose nintedanib and tacrolimus in patients with progressive fibrosing interstitial lung diseases with anti‐ARS antibody‐positive dermatomyositis
حسب: Takeshi Kawaguchi, وآخرون
منشور في: (2024-07-01)

Antifibrotic effect of pyrimidine derivatives of Xymedon and its conjugate with L-ascorbic acid
حسب: G. P. Belyaev, وآخرون
منشور في: (2023-12-01)

Increasing effectiveness of conservative treatment of Peyronie’s disease
حسب: O. B. Zhukov, وآخرون
منشور في: (2018-12-01)

Efficacy of Nintedanib for Idiopathic Pulmonary Fibrosis and Its Safety for Breastfeeding and Pregnancy
حسب: Resyana Santoso, وآخرون
منشور في: (2025-02-01)

Nintedanib for the treatment of symptomatic radiation pneumonitis. A Case Report
حسب: M.E. Kuipers, وآخرون
منشور في: (2024-07-01)

Soluble human macrophage factors are able to inhibit TGF-β-induced differentiation of lung fibroblasts
حسب: A. A. Maksimova, وآخرون
منشور في: (2024-07-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
حسب: N. A. Shostak, وآخرون
منشور في: (2018-06-01)

The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale
حسب: K. V. Zhdanov, وآخرون
منشور في: (2021-01-01)